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BREAKING BARRIERS, PUSHING PROMISE: 
AMERICA’S NEED FOR AN EMBRYONIC 
STEM CELL REGULATORY SCHEME 
INTRODUCTION 
or years, “[b]iomedical researchers have . . . known that their favo-
rite lab critters, mice, have both ‘adult’ and embryonic stem 
cells.”1 In 1998, however, stem cell research was extended to human be-
ings, “in the process touching off a massive ethical and political debate.”2 
Specifically, biologist Dr. James Thomson, a researcher at the University 
of Wisconsin-Madison, and his team published a paper in Science reveal-
ing that they had isolated the very first human embryonic stem cell line.3 
For some, this was a major medical breakthrough, as human embryonic 
stem cell research was expected to have extremely promising health ben-
efits.4 For others, this was the destruction of human life,5 as “the only 
                                                                                                                                  
 1. CHRIS MOONEY, THE REPUBLICAN WAR ON SCIENCE 186 (2006). 
 2. Id. 
 3. James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human Blas-
tocysts, 282 SCIENCE 1145, 1145–47 (1998), available at http://www.sciencemag.org/cgi/ 
reprint/282/5391/1145.pdf. See also NAT’L ACADEMIES, UNDERSTANDING STEM CELLS: 
AN OVERVIEW OF THE SCIENCE AND ISSUES FROM THE NATIONAL ACADEMIES 2 (2006), 
available at http://dels.nas.edu/dels/rpt_briefs/Understanding_Stem_Cells.pdf (In 1998, 
“a team of scientists from the University of Wisconsin-Madison became the first group to 
isolate human embryonic stem cells and keep them alive in the laboratory. The team 
knew that they had in fact isolated stem cells because the cells could remain unspecia-
lized for long periods of time, yet maintained the ability to transform into a variety of 
specialized cell types, including nerve, gut, muscle, bone, and cartilage cells.”). 
 4. See, e.g., Nicholas Wade, Scientists Cultivate Cells at Root of Human Life, N.Y. 
TIMES, Nov. 6, 1998. 
 5. See id. (quoting Dr. Lori Andrews as saying that “[a]ny time you take a[n em-
bryonic] cell off a blastocyst, that cell could be used itself to create a human being, so 
some groups in our society believe in making it transplantable you have derailed it into 
becoming a kidney or some other tissue”). It is to be noted that 
[a]long the wide spectrum of debate, there are those for whom embryonic stem 
cell research is acceptable as long as embryos are used with the consent of the 
egg and/or sperm donors . . . ; there are those who believe it is acceptable as 
long as it is done with embryos that would be destroyed anyway; and there are 
those for whom destroying even these ‘extra’ embryos is abhorrent, and creat-
ing embryos for research or therapy all the more so. 
James Trefil, Brave New World: Everything You Wanted to Know About Stem Cells, 
Cloning, and Genetic Engineering but Were Afraid to Ask, in CRITICAL PERSPECTIVES ON 
STEM CELL RESEARCH 108, 119 (Brian Belval ed., 2006). See also MARSHA GARRISON & 
CARL E. SCHNEIDER, THE LAW OF BIOETHICS: INDIVIDUAL AUTONOMY AND SOCIAL 
REGULATION 841 (2003) (remarking that some argue that “because preeembryos have the 
F 
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way to get such . . . cells was to pluck them from a human embryo sever-
al days after fertilization, destroying the embryo in the process.”6 Cur-
rently, over a decade later, new methods of embryonic stem cell retrieval 
allow for embryo preservation, which may quell much of the ethical de-
bate, and it is commonly understood that embryonic stem cell research 
holds the key to medical advancement and the possibility of curing 
“complex and debilitating diseases and injuries.”7 
Despite the fact that embryonic stem cells are regarded as the holy 
grail of medicine, there is still no American federal regulatory scheme in 
place to deal with such research.8 During his administration, President 
George W. Bush twice vetoed legislation that would support, promote, 
and fund embryonic stem cell research,9 and consequently, individual 
                                                                                                                                  
capacity to become human beings . . . preeembryos are already human lives and thus 
cannot ethically be destroyed to benefit others”). 
 6. Gina Kolata, Scientists Bypass Need for Embryo to Get Stem Cells, N.Y. TIMES, 
Nov. 21, 2007. 
 7. David Baltimore et al., Int’l Soc’y for Stem Cell Research Document, Stem Cell 
Science Leaders Say Nation Must Pursue All Avenues of Stem Cell Research 1 (Sept. 16, 
2008), available at http://www.isscr.org/documents/ScienceStatementSept162008.pdf 
(also referring to embryonic stem cells as the “gold standard”).  
 8. See Kristen Hicks, Note, Embryonic Stem Cell Research and the Theory of Medi-
cal Self-Defense, 21 HARV. J.L. & TECH. 547, 549 (2008) (“[C]urrently no federal law 
supports or bans embryonic stem cell research.”). See also Maneesha Deckha, The Gen-
dered Politics of Embryonic Stem Cell Research in the USA and Canada: An American 
Overlap and Canadian Disconnect, 16 MED. L. REV. 52, 71 (2008) (“The American de-
bate at the federal level about the ethics of [embryonic stem cell research] is a product of 
multiple voices with competing values. . . . Yet, competing concerns that other countries 
with more liberal regimes will exceed American technological prowess in [embryonic 
stem cell research] and impair private enterprise, also explain why [President George W. 
Bush’s 2001] federal ban for [embryonic stem cell research] on non-pre-existing stem 
cell lines only affects public funds. The overall American federal position is reasonably 
viewed as a conservative position on [embryonic stem cell research] that matches the 
conservative national position on abortion that is corroding the rights secured in [Roe v. 
Wade].”). It is to be noted, however, that the federal position on embryonic stem cell 
research is changing under the Barack Obama administration. For more information on 
the steps that have been taken by President Obama regarding embryonic stem cell re-
search, see infra note 9.  
 9. In August 2001, President Bush announced that because embryonic stem cell 
research “offers both great promise and great peril,” his administration would limit feder-
al funding for such research to [sixty] pre-existing stem-cell lines. George W. Bush, Pres-
ident, U.S., Remarks on Stem Cell Research (Aug. 9, 2001), available at http://www. 
whitehouse.gov/news/releases/2001/08/20010809-2.html. For a thorough understanding 
of the implications of George W. Bush’s 2001 decision, see MOONEY, supra note 1, at 
188–89 (“George W. Bush’s 2001 decision so dramatically constricted the potential of 
research by limiting federal funding to embryonic stem cell lines already in existence as 
of August 9, 2001. At least for scientists in need of federal funding, the Bush policy ei-
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states have chosen not to wait.10 Several states have not only legalized 
embryonic stem cell research, but also authorized millions in funding and 
                                                                                                                                  
ther entirely blocks or substantially impairs [them from doing so,] . . . not to mention 
stifl[es] more basic research aimed at understanding the properties of human embryonic 
stem cells in the first place. . . . [The Bush-approved lines were limited in number, but] 
hardly represent[ed] the genetic diversity of America, much less the world. . . . Rather, 
they contain[ed] the genes of affluent, mostly white Americans with fertility problems” 
who had sought out IVF, and thus, because not used for implantation, may also “have 
been flawed or undesirable to begin with.”). Despite Bush’s 2001 announcement, re-
search plowed forward. See Roland Jones, After California, More States Eye Stem Cell 
Research, MSNBC.COM, Feb. 9, 2005, http://www.msnbc.msn.com/id/6847933 (discuss-
ing how some states have donated millions to the embryonic stem cell research effort). In 
July 2006, Bush “issued the first veto of his . . . administration[,] . . . rejecting Congress’s 
bid to lift funding restrictions on human embryonic stem cell research.” Charles Babing-
ton, Stem Cell Bill Gets Bush’s First Veto, WASH. POST, July 20, 2006, at A04. And simi-
larly, in June 2007, he vetoed the Stem Cell Research Enhancement Act of 2007, which 
“would have allowed the use of federal funds to support embryonic stem cell research,” 
remarking that “[d]estroying human life in the hopes of saving human life is not ethical—
and it is not the only option before us.” Maura Reynolds, Bush Vetoes Embryonic Stem 
Cell Funding, L.A. TIMES, June 21, 2007, at A12 (discussing Bush’s veto of the Stem 
Cell Research Enhancement Act of 2007).  
  Since President Barack Obama’s induction as the 44th President of the United 
States, the federal position on embryonic stem cells has been changing. President Obama 
is a supporter of the effort and has recently issued an executive order reversing George 
W. Bush’s 2001 directive limiting stem cell research. Exec. Order., Removing Barriers to 
Responsible Scientific Research Involving Human Stem Cells (Mar. 9, 2009), available 
at http://www.whitehouse.gov/the_press_office/Removing-Barriers-to-Responsible-Scien 
tific-Research-Involving-Human-Stem-Cells/. See also Sheryl Gay Stolberg, Obama Lifts 
Bush’s Strict Limits on Stem Cell Research, N.Y. TIMES, Mar. 10, 2009 (explaining Pres-
ident Obama’s executive order and quoting him as saying that “the majority of Ameri-
cans ‘have come to a consensus that we should pursue this research; that the potential is 
great, and with proper guidelines and strict oversight the perils can be avoided’”). Presi-
dent Obama has not, however, addressed “the thorniest question in the debate: whether 
taxpayer dollars should be used to experiment on embryos themselves”; he intends to 
“leave it to Congress to determine whether the long-standing legislative ban on federal 
financing for human embryo experiments should also be overturned.” Sheryl Gay Stol-
berg, Obama Is Leaving Some Stem Cell Issues to Congress, N.Y. TIMES, Mar. 8, 2009. 
See also Maggie Fox, Stem Cell Bill Research Supporters Offer Senate Bill, REUTERS, 
Feb. 26, 2009 (noting how the Stem Cell Research Enhancement Act of 2007, vetoed by 
Bush, has been reintroduced by Senators Tom Harkin and Arlen Specter). Thus, as it 
stands on March 11, 2009, President Obama’s new executive order will open the door for 
change, but federal funding has not been approved, nor has an embryonic stem cell regu-
latory scheme been established.  
 10. See, e.g., Richard Guerra, States Take the Initiative to Regulate and Resolve the 
Stem Cell Debate, 7 FLA. COASTAL L. REV. 35, 39 (2005) (“In the absence of federal reg-
ulation on the issue, states have been busy developing their own legislation regulating 
research, funding and possible liabilities associated with stem cell research and human 
embryonic cloning.”). George W. Bush’s decision to decline to fund the embryonic stem 
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developed institutes to administer state stem cell research programs.11 
California, for example, passed Proposition 71 in November of 2004,12 
which 
provided $3 billion in funding for [all kinds of] stem cell research at 
California universities and research institutions . . . and called for the 
establishment of a new state agency [the California Institute for Rege-
nerative Medicine] to make grants and provide loans for stem cell re-
search, research facilities and other vital research opportunities.13 
However, there are also states that specifically prohibit most or all 
forms of embryonic stem cell research, like Arkansas, Louisiana, North 
Dakota, and South Dakota.14 Other states, like Iowa, permit embryonic 
stem cell research but do not fund the effort.15 States like North Carolina 
and West Virginia have no law on the subject.16 And some states are 
                                                                                                                                  
cell research effort has also spurred a bit of a “brain drain,” as some researchers have 
opted to move to other countries, such as “Britain, Singapore and China, where the gov-
ernments [a]re more receptive to their work.” Alice Park, The Quest Resumes, TIME, Feb. 
9, 2009, at 41. See also Embryonic Stem Cells: Can I Serve You Now?, ECONOMIST, Jan. 
31, 2009, at 85 (noting that with a federal regulatory scheme supporting embryonic stem 
cell research, “American academics will no longer have to watch enviously from the 
sidelines as their colleagues in Australia, Britain, China, the Czech Republic, Israel, Sin-
gapore and South Korea push ahead”). 
 11. These states include California, Connecticut, Illinois, Maryland, Massachusetts, 
New Jersey, New York, and Wisconsin. See Christine Vestal, Stem Cells: States Divide, 
STATELINE.ORG, June 21, 2007, http://www.stateline.org/live/details/story?contentId=218416 
(last visited Jan. 11. 2009); National Conference of States Legislatures, State Embryonic 
and Fetal Research Laws, http://www.ncsl.org/programs/health/Genetics/embfet.htm (last 
visited Jan. 11, 2009). Most recently, Michigan voted in favor of Proposal 2 in November 
of 2008, legalizing embryonic stem cell research so long as the embryos used for such 
research would otherwise be discarded, and allowing for government funding. See Jeff 
Karoub, Michigan Voters Approve Stem Cell Research Measure, CHI. TRIB., Nov. 5, 
2008. 
 12. California Gives Go-Ahead to Stem-Cell Research, MSNBC.COM, Nov. 3, 2004, 
http://www.msnbc.msn.com/id/6384390/ [hereinafter California Gives Go-Ahead]. 
 13. California Institute for Regenerative Medicine, http://www.cirm.ca.gov/ [herei-
nafter CIRM] (last visited Nov. 3, 2008). 
 14. National Conference of States Legislatures, supra note 11. See also Guerra, supra 
note 10, at 41–42 (noting that South Dakota law, like Arkansas law, “has the effect of 
banning any and all forms of embryonic stem cell research regardless of the possible 
therapeutic applications that the research was designed to explore”). 
 15. Iowa’s Stem Cell Research Enhancement Act, passed in 2007, repealed a prior 
ban on embryonic stem cell research and ensured the research’s legality. See Vestal, su-
pra note 11; Press Release, Office of Governor Chet Culver, Gov. Culver Provides Facts 
on Stem Cell Research (Feb. 14, 2007). 
 16. National Conference of States Legislatures, supra note 11. 
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deadlocked on the issue, like Florida.17 Clearly, “a void of nationally co-
hesive regulation on the issue [of embryonic stem cell research] re-
mains,”18 and this lack of uniformity among states will cause only some 
states to prosper economically and medically, with others lagging be-
hind.19 It will also be difficult for researchers to engage in interstate col-
laboration.20 Most importantly, however, this wide range of embryonic 
stem cell research policy and regulation makes the United States look 
polarized and in disarray, with the more “blue” states surging ahead with 
research and the more “red” states sticking to a conservative approach, 
likely due to religious influence.21 
It is necessary for the United States to construct a federal framework of 
rules and guidelines to govern the use of embryos for research purposes, 
particularly since American society is one that aspires towards both gov-
                                                                                                                                  
 17.  In Florida, two initiatives regarding embryonic stem cell research began circulat-
ing in 2005—one requiring state support of embryonic stem cell research and the other 
prohibiting it. In 2007, the Florida Supreme Court was asked to review these bills be-
cause of their opposition to each other, and it approved both to be placed on the 2008 
ballot. See Advisory Opinion to the Attorney General Re: Funding of Embryonic Stem 
Cell Research, Nos. SC06-2183 & SC06-2261 (May 31, 2007), available at http://www. 
floridasupremecourt.org/decisions/2007/SC06-2183.pdf; Deanna Poole, Stem Cells De-
bated Around Tallahassee, PALM BEACH POST, Apr. 17, 2007, http://www.palmbeach 
post.com/business/content/state/epaper/2007/04/17/a13a_xgr_stemcell_0417.html. The two 
competing proposals failed to make the 2008 ballot, with both initiatives still pending. 
Tim Martin, Michigan Voters to Decide Stem Cell Research Measure, ASSOCIATED 
PRESS, Oct. 4, 2008 (“In Florida, two competing stem cell proposals failed to make the 
ballot this year. One proposal would have banned state funding of embryonic stem cell 
research, while the other would have required the state to provide $20 million a year for 
such research.”). 
 18. Guerra, supra note 10, at 39. 
 19. See, e.g., id. at 39–43. For example, Arkansas and South Dakota, which both, in 
essence, prohibit embryonic stem cell research and development, ranked in 2002 in the 
bottom third of states 
for the total amount that [their] universities expended on research and devel-
opment; . . . for the amount received from the National Institute of Health in 
support of its research institutions; . . . in the amount of higher education de-
grees awarded in the biological sciences; [and] . . . in the amount of biological 
scientists that compromise the[ir] workforce. 
Id. at 41–43 (internal citations omitted). Both states’ employment in the national research 
and development market was 0.1% in 2002. Id. 
 20. Joe Palca, States Take Lead in Funding Stem-Cell Research, NPR.ORG, Mar. 30, 
2007, http://www.npr.org/templates/story/story.php?storyId=9244363. 
 21. See Deckha, supra note 8, at 71 (noting that the embryonic stem cell research 
ethical debate “has occurred in the shadow of a political and legal landscape that is indel-
ibly marked by religious influences and polarized views on abortion and the beginning of 
human life in particular”). 
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ernment monitoring and a green light for research. Countries like the 
United Kingdom22 have thorough regulation for embryonic stem cell re-
search, and even Germany, which has been notoriously “conservative 
about genetic research,”23 has passed the Stem Cell Act of 2008, which 
allows for the importation of “human embryonic stem cell lines that were 
extracted before May 1, 2007.”24 In order for the United States to stay at 
the forefront of medical research, be able to develop new drugs to cure 
disease, and be able to pioneer new technologies to aid in the transplanta-
tion of organs and tissue, our nation needs to dispel ambiguities and unite 
our country’s states with thorough regulation that supports and funds 
embryonic stem cell research.  
This Note will explore the progress of embryonic stem cell research in 
the United States and will argue for thorough federal regulation on the 
subject. Specifically, it will look to the regulatory models in the United 
Kingdom and in the state of California for guidance, as well as the Bush-
vetoed Stem Cell Research Enhancement Act of 2007, and will discuss 
what the best approach is and in which direction the United States ought 
to move. This Note proceeds in four parts. Part I examines why embryo-
nic stem cells are so vital to medical research, as well as how they can 
help our generation and future generations. Part II addresses the tradi-
tional ethical arguments against embryonic stem cell research, looking to 
the pro-life commentary, which argues that it is immoral to use embryo-
nic stem cells for medical experimentation. Part II then explains why the 
medical benefits of embryonic stem cell research trump the moral con-
cerns, particularly in light of new techniques of embryonic stem cell ex-
traction. Part III examines the regulatory models of the United Kingdom 
and California, as well as the Stem Cell Research Enhancement Act of 
2007. Finally, Part IV notes where the three aforementioned models 
                                                                                                                                  
 22. For the regulation in the United Kingdom, see Human Fertilisation and Embry-
ology (Research Purposes) Regulations, No. 188 (2001) (U.K.), available at 
http://www.opsi.gov.uk/SI/si2001/20010188.htm [hereinafter 2001 Regulations] (last 
visited Nov. 3, 2008); Human Fertilisation and Embryology Act, ch. 37 (1990) (U.K.), 
available at http://www.opsi.gov.uk/Acts/acts1990/pdf/ukpga_19900037_en.pdf [he-
reinafter 1990 Act]. See also Select Committee on Stem Cell Research Report, Feb. 13, 
2002, available at http://www.parliament.thestationeryoffice.co.uk/pa/Id200102/Idselect 
/Idstem/83/8302.htm.There is also a pending bill in the United Kingdom termed the 
Human Fertilisation and Embryology Bill [HL] 2007–2008. Human Fertilisation and 
Embryology Bill [HL] (2007–2008) (U.K.), available at http://www.publiccations. 
parliament.uk/pa/cm200708/cmbills/120/2008120.pdf. 
 23. German Lawmakers Loosen Limits on Stem Cell Research, SPIEGEL ONLINE, Apr. 
11, 2008, http://www.spiegel.de/international/germany/0,1518,546867,00.html. 
 24. Dorothee Bürkle, Discussion, Goethe-Institut (Aug. 2008) (Jonathan Uhlaner 
trans.), http://www.goethe.de/wis/fut/thm/deb/en3610292.htm. 
2009] BREAKING BARRIERS, PUSHING PROMISE 537 
agree and divide, and proposes what an American embryonic stem cell 
regulatory model should look like and why. 
I. EMBRYONIC STEM CELL RESEARCH AS HOPE FOR THE FUTURE 
A. Stem Cells: A Background 
A stem cell is a single cell that has the capacity to both replicate itself 
(“self-renew”) and differentiate into many different cell types (“special-
ize”).25 Stem cells are like “blank microchip[s] that can ultimately be 
programmed to perform particular tasks”—under certain conditions, they 
will begin to distinguish themselves and turn into specialized cells that 
carry out a specific function for the body.26 There are three different 
types of stem cells, embryonic stem cells, fetal stem cells, and adult stem 
cells.27 
Five days after a sperm fertilizes an egg, a blastocyst is born—a five-
day-old embryo.28 The blastocyst “contains all the material necessary for 
the development of a complete human being,” but at five days, is “a 
mostly hollow sphere of cells that is [incredibly] small[].”29 Inside the 
interior of the blastocyst is the “inner cell mass, which is composed of 
[thirty to thirty-four] cells that are referred to by scientists as pluripotent 
because they can differentiate into all of the cell types of the body”; these 
inner cell mass cells, when removed, are laced “in a culture dish with a 
nutrient-rich liquid where they give rise to embryonic stem cells.”30 
Fetal stem cells, on the other hand, are derived from fetal tissues and 
are also termed “embryonic germ cells.”31 Fetal stem cells “come from 
the primordial germ cells of a [five to ten] week-old embryo/foetus.”32 
                                                                                                                                  
 25. Deckha, supra note 8, at 55–56; NAT’L ACADEMIES, supra note 3, at 3. 
 26. INT’L SOC’Y FOR STEM CELL RESEARCH, STEM CELL FACTS: THE NEXT FRONTIER? 
(2008), available at http://www.isscr.org/public/ISSCR08_PubEdBroch.pdf. 
 27. Deckha, supra note 8, at 55–56. 
 28. NAT’L ACADEMIES, supra note 3, at 4. 
 29. Id. 
 30. Id. at 4–5. See also Deckha, supra note 8, at 56 (“Embryonic stem cells are ex-
tracted from the inner cell mass of the 4–5 day old embryo, called the blastocyst, which 
consists of 50–150 cells. Embryonic stem cells are pluripotent; they can develop into 
almost all cell types of the foetus and the adult body.”). Yet while embryonic stem cells 
are pluripotent, they are not totipotent—that is, “they cannot develop into placental 
cells.” Id. 
 31. Deckha, supra note 8, at 56. An embryo becomes a “fetus” at eight weeks. Stages 
of Development: Normal Pregnancy: Merck Manual Home Edition, http://www.merck. 
com/mmhe/sec22/ch257/ch257c.html (last visited Jan. 11, 2009). 
 32. Deckha, supra note 8, at 56. 
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They, too, are pluripotent, but have different properties, live for less 
time, and “have a more limited range of potential specialization.”33 
Lastly, adult stem cells are stem cells obtainable from adult tissues.34 
While they “retain the ability to renew themselves for the lifetime of the 
organism,”35 they are “not found in all tissues.”36 It is currently being 
debated whether adult stem cells can, like embryonic stem cells, undergo 
transdifferentiation—that is, give rise to a cell of a different tissue type.37 
Moreover, adult stem cells cannot multiply at the rate of embryonic stem 
cells38 and are “difficult to identify, isolate, maintain, and grow in the 
laboratory.”39 
B. Why Scientists Are Particularly Interested in Embryonic Stem Cells 
Embryonic stem cells are the most versatile type of stem cell because 
“they have the potential to produce every [single] cell type in the human 
body.”40 Their ability to self-renew quickly is also very beneficial, as 
“just a few embryonic stem cells can build a large bank of stem cells to 
be used in experiments.”41 Accordingly, scientists believe that human 
embryonic stem cells have “great scientific, technological and therapeu-
tic potential.”42 Namely, embryonic stem cells “could generate specia-
                                                                                                                                  
 33. Id. See also University of Edinburgh: Social and Political Studies, What is Stem 
Cell Research?, http://www.talkingstemcells.ed.ac.uk/index.php?action=ShowAll&id=12 
(last visited Nov. 3, 2008) (“The advantages of foetal stem cells are that they are easy to 
collect and they have a lower rejection rate compared to bone marrow transplants. Be-
cause of targeted collections, they also offer a greater chance of transplant matches for 
ethnic minorities . . . . [However, t]he risk of transmitting illness through foetal stem cells 
. . . raises new problems that scientists and clinicians have to address. Since this research 
is new and experimental, it is still unclear what the specific risks are or how to resolve 
them.”). 
 34. Deckha, supra note 8, at 56; NAT’L ACADEMIES, supra note 3, at 8. 
 35. Deckha, supra note 8, at 56. 
 36. NAT’L ACADEMIES, supra note 3, at 8. 
 37. Suzanne Kadereit, The Plasticity of Stem Cell Plasticity, ISSCR.ORG, Apr. 2004, 
at 1, available at http://www.isscr.org/scientists/TOM/printversions_archive/TOM_Apr_ 
04.pdf. 
 38. Deckha, supra note 8, at 56. 
 39. NAT’L ACADEMIES, supra note 3, at 8. 
 40. Id. at 5. 
 41. Id. However, “undifferentiated stem cells [cannot] be used directly for tissue 
transplants because they can cause a type of tumor called a teratoma. To be used for ther-
apies, embryonic stem cells would first need to be differentiated into specialized cell 
types.” Id. 
 42. Natasha Hammond & Soren Holm, Resolving the “Egg Supply Problem” in Hu-
man Embryonic Stem Cell Derivation Through Technical Means—A Legal and Ethical 
Analysis, 27 MED. & L. 167, 167 (2008). 
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lized tissue for transplantation”43 and could be used “to treat currently 
untreatable diseases such as Parkinson’s Disease, diabetes, traumatic 
spinal cord injury, and heart disease.”44 
Yet, many believe that “anything that can be done with embryonic 
stem cells can be accomplished with adult stem cells,”45 and that the 
plasticity of stem cells—that is, their ability to differentiate into a variety 
of cell types—is equivalent to that of embryonic stem cells. Much re-
search indicates that “adult stem cells continue to ignore the dogma of 
developmental biology, [for example] . . . blood cells switching to lung 
cells.”46 Other studies, such as a highly regarded study conducted by Irv-
ing Weissman of Stanford University and Amy Wagers of Harvard Uni-
versity, indicate that plasticity “may not be a biological principle but ra-
ther an experimental peculiarity.”47 Specifically, Weissman and Wagers’ 
study noted both technical problems and cell fusion, “resulting in cells 
that masquerade as ‘transdifferentiated’ cells.”48 Weissman and Wagers 
also “combed through the [existing] literature” and concluded “that re-
ports of adult stem plasticity may be due to other reasons than cells 
switching their fates.”49 As the plasticity of adult stem cells is controver-
sial, it is clear that for the moment embryonic stem cells have greater 
therapeutic power. Thus, research must be conducted on embryonic stem 
cells in order to break ground on medical therapies and procedures. 
Lawrence S. B. Goldstein, a professor at the University of California-
San Diego and the Director of the UC San Diego Stem Cell Program,50 
explained in a 2004 speech at Rice University why researchers are inter-
ested in embryonic stem cell research. Goldstein stated that “because of 
their unique attributes, embryonic stem cells could help us bypass four 
current ‘bottlenecks’ in the development of medical therapies.”51 His 
theory is as follows: 
                                                                                                                                  
 43. MOONEY, supra note 1, at 187. 
 44. Yi-Chen Su & Albert Wai-Kit Chan, Mary Doe’s Destiny: How the United States 
Has Banned Human Embryonic Stem Cell Research in the Absence of a Direct Prohibi-
tion, 14 RICH. J.L. & TECH. 12, ¶ 11 (2008), http://law.richmond.edu/jolt/v14i4/article12.pdf. 
 45. CHRISTOPHER THOMAS SCOTT, STEM CELL NOW 89 (2006). 
 46. Id. at 90 (reports by the Karolinska Institute in Sweden). 
 47. Id. at 91. For the study itself, see Amy Wagers et al., Little Evidence for Deve-
lopmental Plasticity of Adult Hematopoietic Stem Cells, 297 SCIENCE 2256, 2256–59 
(2002). 
 48. Kadereit, supra note 37, at 1. 
 49. SCOTT, supra note 45, at 91, 93. 
 50. See News Release, Debra Kain, UC San Diego Appoints Larry Goldstein Director 
of Stem Cell Research Program, Sept. 22, 2006, available at http://ucsdnews.ucsd.edu/ 
newsrel/health/goldstein06_a.asp. 
 51. MOONEY, supra note 1, at 187. 
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First, there [are not] enough sources of tissues for transplantation to 
meet medical needs at present, but we might grow vast amounts of tis-
sues from embryonic stem cells. Second, drugs are extremely expensive 
to bring to market because of the cost of human trials and because ani-
mal trials can often lead scientists down the wrong road, but drug dis-
covery might proceed much more efficiently if we could test drugs in 
human stem cell preparations. Third, we currently lack a complete un-
derstanding of the mechanisms by which many diseases develop, but 
research on stem cells bearing the generic signature for various diseases 
would allow for greater understanding of how these conditions emerge 
(which, in turn, could suggest new possibilities for treatment). And fi-
nally, we see enormous variations among individuals when it comes to 
their responses to various drugs and other therapies, but certain kinds of 
stem cells would eventually lead to therapies specially tailored to indi-
vidual patients.52 
Goldstein’s explanation clearly demonstrates that stem cell research is 
“not a one trick pony,” but rather, a “broad enabling technology” that 
could help us in many different areas of medicine.53 
II. DEFEATING THE ETHICAL CONCERNS 
A. The Traditional Argument: The Moral Status of the Embryo 
“In the field of regenerative medicine, embryonic stem cell re-
search holds far-reaching promise in alleviating and preventing 
an array of debilitating diseases and conditions. Yet the biggest 
ethical stumbling block continues to be conflicting beliefs about 
the moral status of the human embryo.”54 
As the traditional method of removal for embryonic stem cells destroys 
the blastocyst, many have argued that this involves the “intentional[] 
creati[on of] a blastocyst that will never develop into a human being,” 
and, accordingly, that it is immoral to use them for medical experimenta-
tion.55 Much of the traditional argument has religious influence, particu-
                                                                                                                                  
 52. Id. at 187–88 (discussing Goldstein’s speech at the Stem Cells: Saving Lives or 
Crossing Lines—Human Embryonic Stem Cell Policy forum at Rice University in 2004). 
See also Stem Cells: Saving Lives or Crossing Lines—Program Day 1, http://www.ruf. 
rice.edu/~neal/stemcell/program1.html (last visited Nov. 4, 2008) (demonstrating that Dr. 
Goldstein delivered this speech). 
 53. MOONEY, supra note 1, at 188. 
 54. Michael Brannigan, Fixations on the Moral Status of the Embryo, in BIOMEDICAL 
ETHICS REVIEWS: STEM CELL RESEARCH 41, 41–57 (James H. Humber & Robert F. Al-
meder eds., 2004). 
 55. NAT’L ACADEMIES, supra note 3, at 6. 
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larly that of the Roman Catholic Church, which “has declared its formal 
opposition to [embryonic stem cell research] despite the prospective 
medically beneficial potential, urging . . . lawmakers and scientists to 
promote the use of methods that would not entail resorting to embryos 
for stem cell research.”56 The Church believes that “life and personhood 
begins at conception and that [pre]embryos are sacred forms of life be-
cause they are human beings who deserve the respect and protection that 
being human affords.”57 Persons of the Eastern Orthodox Christian, Is-
lamic, and Protestant faiths have also expressed their opposition to em-
bryonic stem cell research, often utilizing a “sanctity of life” argument.58 
Pro-life advocates have also had a “prominent voice shaping [embryo-
nic] stem cell discourse,” particularly in spurring opposition to it.59 The 
religious and anti-abortion views are very similar: both follow the idea 
that “human life is sacred and personhood begins at conception.”60 How-
ever, since abortion law and politics is such a dense topic, I have chosen 
to limit Part II(a) of this Note to a synopsis of the traditional argument 
against embryonic stem cell research, and would merely like to note that 
some courts have viewed pre-embryos as humans in wrongful death ac-
tions and have “increase[d] the scope and nature of the interest that states 
can recogni[z]e in fetuses when regulating abortion,”61 which not only 
puts Roe v. Wade in “precarious standing” but also demonstrates the im-
pact of pro-life philosophy on American decision making.62 
                                                                                                                                  
 56. Deckha, supra note 8, at 62. 
 57. Id. at 63. 
 58. Id. But see Margaret A. Farley, Roman Catholic Views on Research Involving 
Human Embryonic Stem Cells, in THE HUMAN EMBRYONIC STEM CELL DEBATE (Suzanne 
Holland, Karen Lebacqz & Laurie Zoloth eds., 2001) (noting that while some Roman 
Catholics disagree with embryonic stem cell research, there is also “a case for human 
embryo stem cell research . . . within the Roman Catholic tradition,” since “[g]rowing 
numbers of Catholic moral theologians, for example, do not consider the human embryo 
in its earliest stages (before development of the primitive streak or implantation) to con-
stitute an individualized human entity with the settled inherent potential to become a 
human being.”). However, there is “widespread Jewish support for stem-cell research . . . 
[partly because of] the high regard that ‘the Jewish vision places on life and on healing . . 
. and on the good of medicine.’” The Moral Status of the Embryo, HARV. MAG., May–
June 2007, at 66–67, available at http://harvardmag.com/pdf/2007/05-pdfs/0507-66.pdf. 
See also Elliot N. Dorff, Stem Cell Research—A Jewish Perspective, in THE HUMAN 
EMBRYONIC STEM CELL DEBATE, supra (explaining why the Jewish tradition may allow 
for embryonic stem cell research). 
 59. Deckha, supra note 8, at 64. 
 60. Id. at 65. 
 61. Id. 
 62. Id. at 65–67. 
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Opponents of embryonic stem cell research believe that the blastocyst 
possesses a moral status,63 and because “we tend to think of moral status 
as simply being synonymous with the ownership of moral rights . . . 
moral status equals having moral rights.”64 Thus, for the person who be-
lieves blastocysts should have moral status, since “there is no more fun-
damental moral right than the right to exist . . . [and] the moral right to 
exist is fundamental . . . [t]he moral right to exist is therefore a founda-
tional right.”65 Some scholars have argued that there should be more 
flexibility with regard to the moral status of the blastocyst,66 but staunch 
pro-life advocates see the blastocyst’s moral status as static.67 
B. The Benefits of Embryonic Stem Cell Research Trump the Moral 
Argument 
Legal, medical, and sociological scholars alike have stated that em-
bryonic stem cells “have the potential to provide a limitless source of 
specific cell types for transplantation,”68 organ creation, tissue regenera-
tion, nerve repair, and so on, which could aid in alleviating the “debilitat-
ing conditions”69 of so many persons around the globe. Michael Branni-
gan has argued that “[b]ecause the benefits of embryonic stem cell re-
search clearly outweigh the burdens, the moral status of [persons who 
                                                                                                                                  
 63. See, e.g., ROBERT P. GEORGE & CHRISTOPHER TOLLEFSEN, EMBRYO: A DEFENSE OF 
HUMAN LIFE 202–03 (2008) (arguing that pre-embryos are human beings, that “any 
scientific research conducted on embryonic humans, and destructive of their life or 
health, is wrong, immoral, unjust,” and that “[n]o scientist, or any other agent, should 
ever willingly engage in activities that would deliberately threaten the life or health of 
human beings at any stage of development or in any condition”). 
 64. Brannigan, supra note 54, at 45. 
 65. Id. Brannigan constructs his “equation” as follows: “moral status equals possess-
ing moral rights equal possessing the right to exist.” Id. Accordingly, for a person fixated 
on the moral status of the blastocyst, establishing that the blastocyst does indeed have 
such a status leads to the necessary conclusion that the blastocyst “has an absolute right 
to an existence.” Id. 
 66. See, e.g., id. at 54. See also Brent Waters, Does the Embryo Have a Moral Sta-
tus?, in GOD AND THE EMBRYO: RELIGIOUS VOICES ON STEM CELLS AND CLONING 64–76 
(Brent Waters & Ronald Cole-Turner eds., 2003) (Although a Christian who finds him-
self ambivalent towards embryonic stem cell research, Waters does find there to be many 
problems with assigning a “moral status” to the embryo, and suggests viewing the emb-
ryo as a “neighbor,” rather than an “abstract object[] to which . . . [there] must [be] as-
sign[ed] a value or moral status.”). 
 67. See, e.g., GEORGE & TOLLEFSEN, supra note 63, at 22 (“We argue in this book that 
embryonic human beings deserve full moral respect.”). 
 68. James A. Thomson, Human Embryonic Stem Cells, in THE HUMAN EMBRYONIC 
STEM CELL DEBATE, supra note 58, at 22. 
 69. Brannigan, supra note 54, at 52. 
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suffer from debilitating diseases and conditions] clearly ha[ve] priority 
over the moral status of the early embryo.”70 Brannigan joins philosopher 
Mary Anne Warren in arguing for a sliding-scale approach to moral sta-
tus.71 While I will not go to the same extent as Brannigan to say that the 
moral status of diseased persons trumps the moral status of the blasto-
cyst, under a cost-benefit analysis, this nation should fully support em-
bryonic stem cell research by implementing a federal regulatory scheme 
so that “other countries will no[t] . . . outpace the United States in em-
bryological science.”72 
With the benefits being so great—the capacity to understand disease, 
the potential to save so many peoples’ lives, and the ability to remain at 
the forefront of medical research and development—it is difficult for the 
moral argument to trump the need for this kind of medical research. Uti-
litarian ethicists would agree that the ultimate beneficence of this science 
justifies the cost,73 particularly because adult stem cell research is not an 
alternative that would rationalize abandoning the great promise of em-
bryonic stem cell research. Furthermore, embryonic stem cell research 
still shows respect to the embryo, just “respect of a different kind”: as 
argued by Heather Johnson Kukla, “by allowing spare embryos to be 
used in stem cell research to enhance the lives of people who otherwise 
would continue to suffer,” the embryo becomes “a powerful symbol of 
human life [and] . . . more respected and valued . . . than when it is simp-
ly discarded.”74 
Another argument in favor of embryonic stem cell research is that the 
blastocysts used in such research are doomed for destruction anyway, 
and serve no other purpose. Embryonic stem cells traditionally come 
from blastocysts created at fertility clinics, and “[b]ecause not all the fer-
tilized eggs are implanted [in the woman’s womb], a large bank of 
‘excess’ blastocysts [remains with many blastocysts] that are currently 
                                                                                                                                  
 70. Id. 
 71. Id. at 41–57. 
 72. Id. at 55. 
 73. See, e.g., Marianne Means, Editorial, Undeveloped Human Tissue Can Help Save 
the Living, SEATTLE POST-INTELLIGENCER, Sept. 28, 2000, at B4 (“The political struggle 
over abortion intrudes once again on an issue crucial to the health of millions of Ameri-
cans, pitting reverence for undeveloped, unborn human tissue against potential advances 
in medical treatment for living men, women and children. . . . Where should the compas-
sion lie? With inanimate, non-breathing embryonic stem cells or disabled and sick friends 
and family members needing medical help? No contest, I say. Save the living.”). 
 74. See, e.g., Heather Johnson Kukla, Note, Embryonic Stem Cell Research: An Ethi-
cal Justification, 90 GEO. L.J. 503, 531 (2002). 
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stored in freezers around the country.”75 These in-vitro fertilization 
(“IVF”) leftovers, if not used for a future pregnancy, donated to another 
couple, or used for research, are discarded,76 so they might as well pro-
vide researchers with the opportunity to “learn[] about early human deve-
lopmental processes that they otherwise can[not] access, modeling dis-
ease and establishing strategies that could ultimately lead to therapies to 
replace or restore damaged tissues.”77 
C. Reducing Controversy: Blastomere Biopsy 
In order to reduce controversy, scientists have strived to find other me-
thods for producing embryonic stem cells that do not damage the emb-
ryo.78 Most recently, a new technique known as blastomere biopsy has 
come about, which relies on the pre-implantation genetic diagnosis 
(“PGD”) procedure.79 Blastomere biopsy is “performed on a two-day-old 
embryo, after the fertilized egg has divided into eight cells, known as 
blastomeres.”80 When a woman is undergoing IVF at a fertility clinic, 
“the embryo is available outside the woman” and “one of these blasto-
                                                                                                                                  
 75. NAT’L ACADEMIES, supra note 3, at 5. See also Deckha, supra note 8, at 57–58; 
INT’L SOC’Y FOR STEM CELL RESEARCH, supra note 26, at 3. 
 76. What to Do with Leftover Embryos in Fertility Clinics?, SCIENCEDAILY.COM, 
Sept. 25, 2008, http://www.sciencedaily.com/releases/2008/09/080924162942.htm. 
 77. INT’L SOC’Y FOR STEM CELL RESEARCH, supra note 26, at 4. 
 78. This Note will discuss the blastomere biopsy procedure, but there is another po-
tential source of embryonic stem cells: somatic cell nuclear transfer (“SCNT”). SCNT is 
a process by which “an egg has its original nucleus including its genetic material re-
moved and replaced with that of a donor cell[, the ‘somatic cell’]. The egg is then coaxed 
into developing as if it had been fertilized, dividing to the blastocyst stage from which 
embryonic stem cells can be derived.” INT’L SOC’Y FOR STEM CELL RESEARCH, supra note 
26, at 4. See also Deckha, supra note 8, at 58 (“SCNT refers to the cloning method whe-
reby the nucleus of a donor cell . . . itself is implanted into an egg from which the nucleus 
has been removed. The egg is then electrically charged to simulate fertilization.”). SCNT 
involves no sperm and “[c]loning occurs because the receiving enucleated egg starts to 
grow as an embryo, but carries the identical genetic makeup of the donor somatic cell, 
that has not been mixed or adulterated with genetic information from a second person 
through sperm.” Deckha, supra note 8, at 58. As SCNT is a cloning procedure, it is ex-
tremely controversial. See id. Furthermore, “[the] method has been shown to work for 
certain animals such as mice but has proven extremely difficult in humans.” INT’L SOC’Y 
FOR STEM CELL RESEARCH, supra note 26, at 4. 
 79. PGD “is a marriage of IVF and prenatal diagnosis” and “involves two stages: 
IVF/embryo biopsy and genetic testing” in order to detect genetic defects in embryos 
created via IVF. JOYCE C. HARPER, JOY D.A. DELHANTY & ALAN H. HANDYSIDE, 
PREIMPLANTATION GENETIC DIAGNOSIS 3 (2001). 
 80. Nicholas Wade, Stem Cell News Could Intensify Political Debate, N.Y. TIMES, 
Aug. 24, 2006 (noting critics’ objections to the blastomere biopsy procedure). 
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meres can be removed for diagnostic tests, like for Down syndrome.”81 If 
there are no abnormalities found when that single blastomere is tested, 
then the embryo, now with seven cells, can “be implanted into a mother’s 
womb,”82 and the extracted blastomere can be used for research. This 
procedure differs from the traditional method of embryonic stem cell 
retrieval in that it derives the cells at an earlier stage of development, and 
instead of destroying the embryo, leaves the embryo intact.83 
The pioneer of this procedure, Dr. Robert Lanza, has stated that ex-
tracting the blastomere (that is, the embryonic cell) is unlikely to pose 
any additional risk to the embryo,84 other than the risks inherent in PGD, 
and that the procedure itself “does not itself harm or destroy embryos,” 
making it morally acceptable.85 That is not to say that blastomere biopsy 
is perfect and without controversy. Ethical questions still abound, as it is 
uncertain whether the procedure will always be safe for the resulting fe-
tus and child,86 and there is still a risk that embryos may be harmed or 
destroyed.87 PGD currently has an embryo survival rate of eighty per-
cent,88 and while Dr. Lanza “s[eeks] to piggyback on [PGD’s] safety 
                                                                                                                                  
 81. Id. 
 82. Dan Vergano, Embryos Spared in Stem Cell Creation, USA TODAY, Aug. 23, 
2006, available at http://www.usatoday.com/tech/science/discoveries/2006-08-23-stem-cell- 
breakthrough_x.htm. 
 83. Karen Kaplan, Stem Cell Advance Spares Embryos, L.A. TIMES, Aug. 24, 2006, at 
A1; Helen Pearson, Early Embryos Can Yield Stem Cell . . . And Survive, 442 NATURE 
858, Aug. 24, 2006. 
 84. I. Klimanskaya et al., Human Embryonic Stem Cell Lines Derived from Single 
Blastomeres, 444 NATURE 481, 481 Nov. 23, 2006, abstract available at http://www. 
nature.com/nature/journal/v444/n7118/abs/nature05142.html (last visited Jan.11, 2009); 
Wade, supra note 80, ¶ 15. See also Editorial, A Way Out? Scientists Might Now Be Able 
to Harvest Stem Cells Without Harming Embryos, WASH. POST, Aug. 28, 2006, at A14 
[hereinafter Editorial] (discussing blastomere biopsy, why it could defeat the moral ar-
gument, and why federal regulation and funding for embryonic stem cell research should 
be possible). 
 85. Ethics Advisory Board for Advanced Cell Technology, Inc., Human Embryonic Stem 
Cell Lines Derived from Single Blastomeres, http://www.advancedcell.com/recent-news- 
item/ethics-advisory-board-for-advanced-cell-technology-inc-human-embryonic-stem-cell-li 
nes-derived-from-single-blastomeres [hereinafter ACT] (last visited Nov. 4, 2008). 
 86. Cynthia S. Marietta, Comment, Embryonic Stem Cell Research Debate Indirectly 
Focuses Spotlight on Safety of Pre-implantation Genetic Diagnosis, HEALTH L. PERSPS., 
June 11, 2008, at 3, available at http://www.law.uh.edu/healthlaw/perspectives/2008/(CM) 
%20pgd.pdf; Pearson, supra note 83, at 858. 
 87. Marietta, supra note 86, at 3. 
 88. Brandon Keim, Embryonic Stem Cells Created Without Harming Embryo, for 
Real This Time, WIRED, Jan. 10, 2008, at 2, available at http://www.wired.com/medtech/ 
stemcells/news/2008/01/blastocyst_biopsy. 
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record,”89 such may seem too low for staunch pro-life advocates.90 But if 
Lanza’s predictions for the safety of blastomere bioscopy are indeed cor-
rect, this may reduce the controversy that surrounds embryonic stem 
cells. 
Currently, “there [is] no evidence that a single blastomere [removed 
during the blastomere biopsy procedure] could develop into a person.”91 
If it were proven that a single blastomere could never become a human 
being, then there is no pro-life, religious argument for challengers to rely 
on. In sum, assuming the blastomere biopsy procedure is thoroughly vet-
ted and everything articulated by its pioneers is “demonstrated to be via-
ble,”92 there leaves no “rational reason[, or moral one, for that matter,] to 
oppose this [method of extraction and embryonic stem cell] research.”93 
D. Embryonic Stem Cell Near Equivalents 
Researchers have also been busy creating embryonic stem cell near 
equivalents. Harvard University researchers have created induced pluri-
potent stem cells (“iPS cells”)—that is, they have induced “adult stem 
cells into an embryonic-like state without forming tumors,” which “are 
one of the efficacy problems, along with immune system rejection issues, 
that plague embryonic stem cells.”94 However, the success of iPS cells 
has only been demonstrated in mice.95 Scientists have also recently re-
                                                                                                                                  
 89. Kaplan, supra note 83, ¶ 17. There is little comprehensive data about PGD’s ac-
curacy and the effects it has on children. See, e.g., Susannah Baruch et al., Genetic Test-
ing of Embryos: A Critical Need for Data, 11 REPROD. BIOMED. ONLINE (No.6) 667, 
667–70 (2005) (commenting on the lack of PGD data and conducting a survey regarding 
the practices and beliefs of IVF clinic directors with respect to PGD). 
 90. See Wade, supra note 80 (noting critics’ objections to the blastomere biopsy pro-
cedure). 
 91. Id. ¶ 29. 
 92. Editorial, supra note 84, ¶ 5. 
 93. Wade, supra note 80, ¶ 7. 
 94. Steven Ertelt, Ethical Embryonic Stem Cell Research Alternative Crosses Another 
Hurdle, LIFENEWS.COM, Sept. 26, 2008, at 1, http://www.lifenews.com/bio2588.html. 
The study, conducted by Matthias Stadtfeld, Masaki Nagaya, Jochen Utikal, Gordon 
Weir, and Konrad Hochedlinger, was published in Science. Matthias Stadtfeld et al., In-
duced Pluripotent Stem Cells Generated Without Viral Integration, 322 SCIENCE 945 
(2008), abstract available at http://www.sciencemag.org/cgi/content/abstract/sci;322/59 
03/945?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=konrad+hoche
dlinger&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT (last visited Nov. 3, 2008). 
See also Stem Cell Briefing for ISSCR M. William Lensch, Breakthroughs in Stem Cell 
Biology: Human iPS Cells, Feb. 27, 2008, available at http://www.isscr.org/public/ 
briefings/breakthrough.html. 
 95. Ertelt, supra note 94, at 1. See also Park, supra note 10, at 43 (“iPS cells have yet 
to prove that they are a safe and suitable substitute for the diseased cells they might even-
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ported being able to “turn[] human skin cells into what appear to be em-
bryonic stem cells without having to make or destroy an embryo,”96 but 
these near equivalents “might not be medically ready for years and they 
might never be as powerful as [embryonic stem cells].”97 Thus, “[u]ntil 
those [skin] cells [or iPS cells] are ready, . . . research on embryonic stem 
cells is still required.”98 
III. REGULATORY MODELS—THE CALIFORNIAN, THE ENGLISH, AND THE 
PROPOSED U.S. FEDERAL 
Knowing that embryonic stem cell research is the key to medical ad-
vancement, and assuming that embryonic stem cell research opponents 
have been painted into a corner, it is clear that the United States needs 
federal regulation for embryonic stem cell research. Thus, the question is 
not whether the nation needs it, but rather, what provisions it should in-
clude. For guidance, this Note will examine two regulatory models—that 
of the state of California, the U.S. state most recognized for its embryo-
nic stem cell research regulation and funding, and that of the United 
Kingdom, a nation that has had embryological science law in place for 
decades. This Note will then look at the proposed Stem Cell Research 
Enhancement Act of 2007, which was vetoed by President George W. 
Bush. 
A. California’s Proposition 71 
On November 2, 2004, California passed Proposition 71, “a controver-
sial bond measure that devote[d] $3 billion to human embryonic stem 
cell experiments and comprise[d] the biggest-ever state-supported scien-
tific research program in the country.”99 Proposition 71 established the 
California Institute for Regenerative Medicine (“CIRM”) and its Inde-
                                                                                                                                  
tually replace in a patient,” or that they are “as stable and as versatile as embryonic stem 
cells.”). 
 96. Kolata, supra note 6. See also J. R. Minkel, Human Stem Cell Breakthrough: No 
Embryos Required, SCI. AM., Nov. 20, 2007, available at http://www.sciam.com/article. 
cfm?id=human-stem-cells-no-embryo (“Two groups of researchers report today that 
washing human skin cells in similar cocktails of four genes enabled them to reprogram 
the cells to resemble those harvested from embryos.”). 
 97. Keim, supra note 88, at 2. 
 98. Id. at 2. See also Baltimore et al., supra note 7, at 2 (“[T]he recent success in 
reprogramming adult human cells into cells that closely resemble [embryonic stem] cells 
would not have occurred without the last decade of human [embryonic stem] cell re-
search. . . . [I]t will likely be several years before we know whether the resulting iPS cells 
differ in clinically significant ways from human [embryonic stem] cells . . . [and thus] 
vital research on human [embryonic stem] cells must continue to move forward.”). 
 99. California Gives Go-Ahead, supra note 12, ¶ 1. 
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pendent Citizen’s Oversight Committee (“ICOC”) in order to centralize 
the funding for California’s stem cell research projects, to dole out re-
search grants to state universities and research laboratories, and to “sup-
port and advance stem cell research and regenerative medicine under the 
highest ethical and medical standards.”100 Immediately thereafter, how-
ever, groups opposed to embryonic stem cell research, abortion, and tax-
es challenged the program set forth in Proposition 71,101 arguing “that the 
program . . . violate[d] laws concerning state spending, the structure of 
ballot initiatives [and] rules regarding conflicts of interest.”102 Although 
the state did not issue any of its $3 billion in bonds “[b]ecause of the un-
certainty over the litigation,”103 an appeals court held in their favor in 
February of 2007, which Robert Klein, CIRM’s chairman, “hailed . . . as 
‘one huge step for California.’”104 CIRM has since allocated over $635 
million in grants all over the state, mostly to University of California 
schools and to private research institutes, notably the Salk Institute for 
Biological Studies.105 
Proposition 71, now codified in the California Constitution at Article 
XXXV, provides a right to conduct embryonic stem cell research—to be 
precise, it “established a right to conduct stem cell research . . . [on] adult 
stem cells, cord blood stem cells, pluripotent stem cells, and/or progeni-
tor cells.”106 Under Proposition 71, pluripotent cells are those that are 
“capable of self-renewal, [and also] have broad potential to differentiate 
into multiple adult cell types,”107 a definition which encompasses em-
bryonic stem cells.108 Proposition 71 clearly notes the sources that could 
be used to obtain embryonic stem cells, namely IVF and SCNT,109 but 
also indicates that human reproductive cloning would be neither tolerated 
nor funded.110 
                                                                                                                                  
 100. CIRM, supra note 13. See also California Proposition 71 (codified as California 
Constitution Art. XXXV), available at http://www.cirm.ca.gov/pdf/prop71.pdf [hereinaf-
ter Proposition 71]. 
 101. Cal. Family Bioethics Council v. Cal. Inst. for Regenerative Med., 147 Cal. App. 
4th 1319 (Cal. Ct. App. 2007). 
 102. Andrew Pollack, California Stem Cell Research Is Upheld by Appeals Court, 
N.Y. TIMES, Feb. 26, 2007. 
 103. Id. ¶ 4. 
 104. Id. ¶ 5. 
 105. CIRM: Approved CIRM Grants as of January 2008, http://www.cirm.ca.gov/info/ 
grants.asp (last visited Jan. 23, 2009). 
 106. Proposition 71, supra note 100, § 5. 
 107. Id. 
 108. See supra Part I.A. 
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 110. Id. art. XXXV, § 3. 
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Proposition 71 also amended the California Health and Safety Code, 
notably adding the California Stem Cell Research and Cures Bond 
Act,111 the California Stem Cell Research and Cures Bond Act of 
2004,112 and Definitions.113 Proposition 71 amended the Health and Safe-
ty Code to include public meeting laws for the CIRM’s ICOC;114 a provi-
sion that disallows an ICOC disinterested member to “use his or her offi-
cial position to influence a decision to approve or award a grant, loan, or 
contract to his or her employer,” thus omitting the possibility for con-
flicts of interests;115 a prohibition on compensation to research donors or 
participants in the stem cell research process, but an allowance for the 
reimbursement of expenses;116 a time limit for when embryonic stem 
cells can be extracted from blastocysts, that is, no more than eight to 
twelve days after cell division commences;117 and competitive bidding 
for government-funded grants.118 It is very important to note that Propo-
sition 71 also has a provision that requires the CIRM to create standards 
for obtaining all research donors’ informed consent.119 Now, CIRM’s 
informed consent standards are as follows: 
Because human embryonic stem cell research is controversial, prospec-
tive donors need to be informed as completely as possible about possi-
ble research uses of embryos, gametes, and tissue that they might do-
nate. If donors have stated restrictions on the future uses of donated 
materials, CIRM-funded researchers must respect these. Because it is 
difficult to foresee all future uses, however, researchers are free to util-
ize only materials whose donors have consented to all future research 
uses that are approved by scientific and ethical review bodies. This . . . 
strikes a balance between respecting the informed preferences of do-
nors and maximizing the scientific benefit from research funding.120 
                                                                                                                                  
 111. California Health and Safety Code, §§ 125290.10–125290.70, available at http://law. 
justia.com/california/codes/hsc/125290.10–125290.70.html [hereinafter CSCR&C] (last 
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com/california/codes/hsc/125292.10.html [hereinafter Definitions] (last visited Nov. 5, 2008). 
 114. CSCR&C, supra note 111, § 125290.30(d). 
 115. Id. § 125290.30(g)(1)(A). 
 116. Id. § 125290.35(b)(3). 
 117. Id. § 125290.35(b)(6). 
 118. Id. § 125290.30(f). 
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B. The United Kingdom’s Fertilisation and Embryology Act, Regula-
tions, and Pending Bill 
The United Kingdom’s Fertilisation and Embryology Act of 1990 
(“1990 Act”) established a national Human Fertilisation and Embryology 
Authority (“Authority”) to grant licenses to researchers.121 In order to 
obtain a license for research under the 1990 Act, two criteria must be 
satisfied: first, an application must demonstrate that the activity is “for 
the purpose of . . . (a) promoting advances in the treatment of infertility, 
(b) increasing knowledge about the causes of congenital disease, (c) in-
creasing knowledge about the causes of miscarriages, (d) developing 
more effective techniques of contraception, or (e) developing [abnor-
mality detection] methods for . . . embryos” pre-implantation, and 
second, it must demonstrate that the activity is “necessary or desirable” 
to achieve one of the specified purposes.122 
Because the 1990 Act does not clearly permit stem cell research, in 
2001, Parliament specified that a license may be issued by the Authority 
for the purposes of “(a) increasing knowledge about the development of 
embryos[,] (b) increasing knowledge about serious disease, or (c) enabl-
ing any such knowledge to be applied in developing treatments for se-
rious disease.”123 This can be viewed as an explicit endorsement of em-
bryonic stem cell research by the British government, and the Authority 
soon began to grant licenses for such research.124 
The pending 2007–2008 Human Fertilisation and Embryology Bill 
hopes to supplement the 1990 Act in order for it to remain appropriate 
for the twenty-first century.125 The bill aims to ensure that “all human 
embryos outside the body—whatever the process used in their creation—
are subject to regulation” and that “the scope of legitimate embryo re-
search activities, subject to controls,” is extended.126 The bill will also 
                                                                                                                                  
and Ethical Standards, 4 PLOS MED. 803, 804 (Issue No. 5) (2007), available at 
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1858709&blobtype=pdf. 
 121. See 1990 Act, supra note 22, § 5. 
 122. Id. sched. 2, ¶ 3. 
 123. 2001 Regulations, supra note 22, ¶ 2(2)(a)–(c). 
 124. See, e.g., Emma Young, Human Embryonic Stem Cell Research Begins in U.K., 
NEWSCIENTIST.COM, Mar. 1, 2002, http://www.newscientist.com/article/dn1992-human-
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provide regulation for “‘inter-species’ embryos created from a combina-
tion of human and animal genetic material for research” and will alter the 
“restrictions on the use of data collected by the [Authority] to make it 
easier to do follow-up research.”127 Members of Parliament have backed 
this bill, particularly in its support for the creation of hybrid embryos, 
which have been referred to as “saviour siblings” because of their ability 
to aid in the treatment of debilitating diseases.128 
C. The Vetoed U.S. Stem Cell Research Enhancement Act of 2007 
The Stem Cell Research Enhancement Act of 2007 (“2007 Act”) aimed 
“[t]o amend the Public Health Service Act to provide for human em-
bryonic stem cell research.”129 The 2007 Act explicitly supported human 
embryonic stem cell research and noted that the Secretary would conduct 
such research, meaning that embryonic stem cell research would be fed-
erally funded.130 The 2007 Act also included the creation of guidelines 
and would have mandated that the Secretary comply with some reporting 
requirements.131 Most importantly, however, the 2007 Act provided for 
three ethical obligations to be met in order for human embryonic stem 
cells to be used for research purposes.132 These three requirements were 
as follows: 
1) The stem cells were derived from human embryos that have been 
donated from in vitro fertilization clinics, were created for the purposes 
of fertility treatment, and were in excess of the clinical need of the in-
dividuals seeking such treatment. 
2) Prior to the consideration of embryo donation and through consulta-
tion with the individuals seeking fertility treatment, it was determined 
that the embryos would never be implanted in a woman and would oth-
erwise be discarded. 
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3) The individuals seeking fertility treatment donated the embryos with 
written informed consent and without receiving any financial or other 
inducements to make the donation.133 
President George W. Bush vetoed the 2007 Act, after it passed in the 
House and Senate, on June 20, 2007.134 
IV. WHAT KIND OF FEDERAL REGULATION WOULD BE OPTIMAL? 
A. The Six Elements 
I have isolated six important issues stemming from an analysis of the 
aforementioned regulatory models, as well as the Massachusetts regula-
tory model,135 which is quite thorough, like California’s. These issues 
are, in no order of importance, (1) a centralized agency, (2) the right to 
research, (3) the sources of the human embryonic stem cells, (4) a prohi-
bition on compensation, (5) informed consent, and (6) federal licensing. 
First, the Californian and British regulatory models have both estab-
lished a centralized agency to make grants and loans to researchers, and 
to monitor and report all stem cell activities.136 Yet, a centralized agency 
is not only useful to dole out funds and report where money is going. A 
centralized agency could also encourage cooperation, advocate for a 
common cause, allow for effective monitoring, and could ensure that 
different sorts of projects are pursued in a way that avoids too much 
overlap. Furthermore, a centralized agency could ensure that funds are 
spread across the nation, and could also push for adherence to certain 
ethical standards, as well as medical ones. The vetoed 2007 Act, howev-
er, did not contain a provision to establish such an agency. An American 
federal regulatory agency could be extremely beneficial to an embryonic 
stem cell regulatory scheme, particularly as there has been no prior fed-
eral law on the subject and there is great variance among the states’ 
laws.137 
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 134. Reynolds, supra note 9.  
 135. Massachusetts has a stem cell research regulatory model, despite Governor Mitt 
Romney’s veto, as the state legislature overturned it. See Lawmakers Override Veto of 
Stem Cell Bill, L.A. TIMES, June 1, 2005, at A10. For the text of the Massachusetts sta-
tute, see An Act Promoting Stem Cell Research, S.2032 (Mass. 2005), available at 
http://www.mass.gov/legis/bills/senate/st02/st02032.htm [hereinafter Massachusetts Act] 
(last visited Nov. 5, 2008). 
 136. See supra Part III.A–B. 
 137. See supra Intro. 
2009] BREAKING BARRIERS, PUSHING PROMISE 553 
Second, California’s Proposition 71 explicitly establishes a constitu-
tional right to conduct stem cell research.138 While federal legislators 
may not want to form an absolute right to research,139 one could make the 
argument that “[i]f the First Amendment serves to protect free trade in 
the dissemination of ideas and information, it must also protect the ne-
cessary preconditions of speech, such as the production of ideas and in-
formation through research.”140 Indeed, the government could argue for 
the establishment of a federal right to embryonic stem cell research be-
cause “society must foster bio-scientific inquiry and innovation,”141 es-
pecially in a context such as this, where so many lives could be saved. 
While this argument may satisfy a constitutional rational basis analy-
sis,142 it is unlikely that the government would establish the constitutional 
right to embryonic stem cell research in its first law on the subject. 
Third, Proposition 71 and the vetoed 2007 Act specifically describe 
where embryonic stem cells for research purposes could be obtained. 
California’s Proposition 71 notes IVF and SCNT as both acceptable 
sources for embryos.143 In the first of its three ethical requirements for 
embryonic stem cell research, the vetoed 2007 Act also states that fertili-
ty clinics are an appropriate source for embryos.144 However, the vetoed 
2007 Act does not indicate a position on SCNT, nor does it mention it, 
likely because it involves cloning and is therefore controversial.145 In a 
federal regulatory scheme for embryonic stem cell research, IVF should 
be designated as the primary source for embryos, and if SCNT is ever 
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proven to be extremely successful beyond mice, it too could be added as 
an appropriate source. 
Fourth, California and the vetoed U.S. federal bill both articulate a 
prohibition on compensating embryo donors.146 The United Kingdom’s 
law, as it currently reads, does not have such a prohibition, but this could 
be relevant to the pending 2007–2008 bill. This prohibition is not, how-
ever, uncommon: for example, Massachusetts’ embryonic stem cell regu-
latory scheme provides that “[n]o person shall knowingly purchase or 
sell any pre-implantation embryo for human embryonic stem cell re-
search for valuable consideration,” adding that “reasonable payments 
associated with storage, quality control, preservation, processing or 
transportation of such pre-implantation embryos” are to be excluded 
from the definition of “consideration.”147 The prohibitory language in the 
Massachusetts law does not differ much from California’s, which only 
allows reimbursements to be paid.148 The vetoed 2007 bill articulates that 
nothing ought to induce one to make the embryo donation,149 but its rea-
soning is entirely the same as both states’ provisions: the donation should 
not be coerced or executed out of self-interest. Rather, the donation 
should be voluntary and incentive-free. 
Fifth, Proposition 71 and the vetoed 2007 bill (in the third of its three 
ethical requirements) equally stress the need for informed consent when 
receiving a donated embryo.150 The vetoed 2007 bill states that informed 
consent must be given in written form;151 Proposition 71 does not specify 
the method by which informed consent is to be given.152 Either way, this 
might be one of the most important inclusions in a regulatory scheme for 
embryonic stem cell research. Given that individuals may “suffer a digni-
tary harm by being deprived of their ‘autonomous right to chose’” if they 
are not “adequately equipped with information pertinent to their decision 
about whether or not to participate in [embryo donation],” the informed 
consent procedure is critical to the donor as well as to the embryonic 
stem cell donation process.153 This is likely why Massachusetts has pro-
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vided a lengthy definition of what qualifies as informed consent, articu-
lating the physician’s expansive duties, the need for an informational 
pamphlet to be provided to the patient, and the need for an informed con-
sent form to be fully filled out by both the patient and the physician.154 
Accordingly, it is imperative that a thorough informed consent provision 
be included in a federal embryonic stem cell research regulatory scheme. 
Lastly, the United Kingdom’s 1990 Act established an agency with all 
federal licensing authority, but has requirements that must be met in or-
der to obtain a license for research.155 Particularly after the addition of 
the 2001 Regulations, the United Kingdom’s structure for giving out li-
censes seems especially organized, seeing as everyone’s embryonic stem 
cell activity is authorized and monitored by the government.156 Such a 
licensing structure for embryonic stem cell research could prove benefi-
cial in the United States, as it would create order and cohesion in a sys-
tem that is in disarray. While there are certainly benefits to implementing 
such licensing, there are certainly some complications that could arise, 
notably the typical time delays in dealing with government agencies and 
standards that could prohibit certain kinds of researchers from engaging 
in very promising research. Moreover, some research projects have been 
ongoing for years, and may have multiple phases to them, so it may 
prove difficult to decide at what point it is necessary for the researchers 
to apply for a license. While this qualm could be easily rectified by ex-
cusing ongoing projects from applying for a license for their current 
phase, and requiring them to apply for a license for the next phase, issues 
could still come about if their application for a license is denied. That is, 
any potential benefit gained from the research could be unrealized. More 
comprehensive research must be conducted to determine if federal li-
censing is indeed a beneficial structure for the United States and whether 
or not it will abate the controversies that surround embryonic stem cell 
research. Chances are, however, that most researchers would find a fed-
eral licensing system to be unfeasible in the United States, as it would be 
too costly to implement and administer. 
B. What an American Federal Regulatory Scheme Should Look Like 
As previously mentioned, a federal regulatory scheme for embryonic 
stem cell research should prohibit compensation for donors, and if SCNT 
is proved successful beyond mice, SCNT should be deemed an appropri-
ate source for embryos. Furthermore, if research does reveal that federal 
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licensing would be beneficial to the United States, then such a system 
should also be implemented via a federal licensing authority, such as in 
the United Kingdom. 
The United States should establish a new federal agency under the U.S. 
Department of Health and Human Services to deal with regenerative 
medicine and stem cell research. This agency would be empowered, like 
the Human Fertilisation and Embryology Authority in the United King-
dom and CIRM in California, to delegate federal funds to researchers 
who meet objective criteria of an application process. It would also be 
responsible for federal licensing, if such a system were deemed appropri-
ate for the United States. This new agency would not only fund, monitor, 
and report all stem cell projects, but also affirmatively endorse embryo-
nic stem cell research as medicine’s key to the future. This agency would 
expressly focus on the need for embryonic stem cell research for medical 
advancement. While another federal agency in the U.S. Department of 
Health funds research opportunities—the Agency for Healthcare Re-
search and Quality (“AHRQ”)—the research this agency funds and sup-
ports is broad and focuses more on improving the quality and safety of 
the current healthcare system than on understanding and developing 
treatments for incurable diseases and degenerative conditions.157 Specifi-
cally, the AHRQ’s mission is “to improve the quality, safety, efficiency, 
and effectiveness of health care for all Americans.”158 The mission of a 
regenerative medicine and stem cell research agency would be “to en-
dorse, support and fund regenerative medicine and stem cell research 
projects in order to develop new therapies and treatments for untreatable 
disease and to aid with tissue and organ transplantation.” 
A new federal regulatory scheme should not only establish a new fed-
eral agency, but also explicitly include a thorough informed consent pro-
vision. However, while informed consent is critical for patient autonomy, 
patients should not be inundated with information that merely confuses 
them, as this will not lead to better decision making, which is the goal of 
the informed consent doctrine.159 Furthermore, providing informed con-
sent necessitates an extraordinary expenditure of time, resources, and 
funds. Thus, in deciding what kind of informed consent to provide to 
embryo donors in a U.S. federal regulatory scheme, it is important to 
take into account both the need for patient autonomy as well as the con-
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straints. I propose that a patient give both oral and written consent and 
that a physician engage in dialogue that firmly discloses to the patient 
that her embryos will be used for research, as well as the benefits and 
risks of choosing to donate embryos for research purposes. An explana-
tion of where, how, and why embryonic stem cell research is conducted 
is not mandatory, although a very brief one could be encouraged; elabo-
rate videos, pamphlets, and pictorial displays are excessive. Since emb-
ryo donation for research purposes is not a life-or-death, patient-
determinative medical process, and each donated embryo will undergo 
the same procedure in order to be utilized for research, each patient can 
be told the exact same information by a physician. Accordingly, physi-
cians can adhere to a reasonable physician informed consent standard: he 
or she should disclose all information that would usually be disclosed to 
an embryo donor.160 
Information that should be disclosed to all embryo donors, both in the 
written consent form and by the physician, should be the following: (1) 
that an agreement to donate does not necessarily mean that the embryos 
will be used for research purposes, but that they could be, and if not 
used, or if stem cells cannot be obtained from them, they will be dis-
carded; (2) that any embryonic stem cell line derived from the embryo 
will be anonymized;161 (3) that an embryonic stem cell line can be main-
tained for years, can be transferred among facilities, and can be used for 
various different projects; (4) that a failure to donate will not adversely 
affect the potential donor’s medical care;162 (5) that donors will not re-
ceive any direct financial or personal benefit from donating, but that do-
nation will benefit research to better the social aggregate; (6) that a risk 
of donation is that this embryo will not be able to be used for fertility 
purposes; and (7) that there is a psychological risk of “anxiety or re-
gret.”163 Donors should also be told that they can withdraw their consent 
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up until the stem cells are obtained from the embryos. When procedures 
like blastomere biopsy become commonplace, the language used to dis-
close the above information would be different. For example, “embryo 
donation” would become “embryonic stem cell donation.” Moreover, the 
need to explain to the donor that the donated embryos cannot be used for 
fertility purposes would be eliminated. 
CONCLUSION 
It is critical for the United States to develop a federal regulatory 
scheme for embryonic stem cell research. The range of embryonic stem 
cell research policy and regulation across the fifty states is much too 
wide for a topic so vital to our country’s medical future and, accordingly, 
the United States should endorse, support, regulate, and fund the em-
bryonic stem cell research effort on a federal level. As the principal ob-
jection to embryonic stem cell research, which was also President Bush’s 
objection, can be overcome with new technology such as blastomere bi-
opsy, it is time for the United States to follow many other Westernized 
countries and develop thorough regulation on the subject. Optimal regu-
lation for embryonic stem cell research would articulate the establish-
ment of a centralized federal agency to administer and fund such re-
search, the kind of informed consent to be provided to embryo donors, 
the need for incentive-free embryo donation, the appropriate sources for 
embryos, the fact that such research will be awarded federal funds, and 
the federal government’s active endorsement of the embryonic stem cell 
research effort. Embryonic stem cells hold medicine’s key to the fu-
ture—now all we need is a federal regulatory scheme in place to deal 
with such research. 
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